Key result
Protocatechuic aldehyde competitively inhibits tyrosinase activity in a dose-dependent manner with ~20 µM IC50.
Answers are grounded in this paper and cite their sources.
Demonstrates that protocatechuic aldehyde competitively inhibits tyrosinase activity, indicating its potential for treating human skin pigmentation disorders.
The purpose of this study was to determine the inhibitory action of protocatechuic aldehyde (PCA) on tyrosinase activity. PCA is one of the compounds found in the root of Salvia miltiorrhiza. Our study documented that PCA has a potent inhibitory effect on tyrosinase, which catalyzes the rate-limiting step of melanin biosynthesis. Although melanin biosynthesis has an essential function normally in human skin for defense against ultraviolet light of the sun, its abnormal activity as seen in pigmentation disorder could lead to serious medical problems. Our data showed that PCA, with concentrations ranging from 1 x 10(-5) M to 8 x 10(-5) M, exhibited dose-dependent inhibition of the enzyme activity with 50% of inhibition at 19.92 x 10(-6) M. A further kinetic analysis on PCA inactivation of tyrosinase activity revealed a competitive inhibition of the enzyme at the L-tyrosine binding site. The findings of our present study merit further research on the applicability of PCA as a potential agent for treatment of pigmentation disorder.
No takes yet. Share an insight, caveat, or question.
No et al. (2004) studied Pigmentation disorder. Protocatechuic aldehyde (PCA) was evaluated on Inhibition of tyrosinase activity (IC50 19.92 x 10(-6) M). Protocatechuic aldehyde (1x10^-5 to 8x10^-5 M) competitively inhibited tyrosinase activity in a dose-dependent manner with 50% inhibition at 19.92x10^-6 M.
Synapse has enriched 10 related papers. Consider them for comparative context: